Skip to main content
Equibles

Balyasny Asset Management L.P.

Position in NSRX — Nasus Pharma Ltd

CIK 1218710 Chicago, IL
Back to NSRX Full portfolio

Position in NSRX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$3,144,655
+$1,150,045 QoQ
Shares Held
898,473
0.0% QoQ
Ownership
7.67%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#1
of 10 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NSRX Over Time

Shares Held

Position Value (USD)

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

Balyasny Asset Management L.P. holds $847,064,370 across 13 Drug Manufacturers - General names. NSRX ranks #13 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 151,950 $182,253,403
2 ABBV
AbbVie Inc.
 622,946 $156,758,131
3 JNJ
Johnson & Johnson
 584,500 $148,445,465
4 SNY
Sanofi
 2,405,640 $102,624,602
5 GILD
Gilead Sciences, Inc.
 587,082 $74,171,939
6 BIIB
Biogen Inc.
 265,090 $57,275,345
7 NVO
Novo Nordisk A S
 1,109,982 $53,212,537
8 OGN
Organon & Co.
 2,196,642 $29,742,532

All Filings in NSRX

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,144,655 898,473
2026-03-31 $1,994,610 898,473